Blood distribution of bortezomib and its kinetics in multiple myeloma patients

被引：11

作者：

Osawa, Takashi ^{[1
]}

Naito, Takafumi ^{[1
]}

Kaneko, Takanori ^{[1
,2
]}

Mino, Yasuaki ^{[1
]}

Ohnishi, Kazunori ^{[3
]}

Yamada, Hiroshi ^{[2
]}

Kawakami, Junichi ^{[1
]}

机构：

[1] Hamamatsu Univ Sch Med, Dept Hosp Pharm, Hamamatsu, Shizuoka 4313192, Japan

[2] Univ Shizuoka, Grad Sch Pharmaceut Sci, Dept Drug Evaluat & Informat, Shizuoka 4228526, Japan

[3] Hamamatsu Univ Sch Med, Ctr Oncol, Hamamatsu, Shizuoka 4313192, Japan

来源：

CLINICAL BIOCHEMISTRY | 2014年 / 47卷 / 15期

关键词：

Bortezomib; Blood distribution; Multiple myeloma; Pharmacokinetics; Therapeutic drug monitoring; PROTEASOME INHIBITOR BORTEZOMIB; DRUG-DRUG INTERACTION; ADVANCED SOLID TUMORS; EXTENDED FOLLOW-UP; PROTEIN-BINDING; ERYTHROCYTES; TRIAL; PHARMACOKINETICS; METABOLISM;

D O I：

10.1016/j.clinbiochem.2014.06.077

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Objectives: Pharmacokinetic disposition of bortezomib in the blood has not been fully characterized in humans. This study aimed to evaluate the blood distribution of bortezomib and its kinetics in multiple myeloma patients. Design and method: Eighteen multiple myeloma patients receiving bortezomib-dexamethasone combination therapy were enrolled. Blood specimens were drawn just before bortezomib administration on days 1 and 8 in the second and third cycles and after discontinuation. The relationships between bortezomib concentration and blood components were evaluated. Results: Bortezomib concentration in the blood on day 1 was higher than that on day 8 in the second cycle. No difference was observed in bortezomib blood concentrations between day 8 in the second and third cycles. The bortezomib concentration in the blood and blood cells was 3- and 7-fold higher than that in plasma. Bortezomib concentration in the blood was correlated with the red blood cell count. The half-life of bortezomib in the blood was 23 days. Conclusion: Bortezomib was taken up into red blood cells to only a limited extent and eliminated in parallel to the red blood cells' lifespan. The turnover of red blood cells can affect the pharmacokinetic disposition of bortezomib in multiple myeloma patients. (C) 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

引用

页码：54 / 59

页数：6

共 50 条

[21] Population-based meta-analysis of bortezomib exposure–response relationships in multiple myeloma patients [J].

Li Zhang ;

Donald E. Mager .

Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47 :77-90

[22] Bortezomib treatment for multiple myeloma [J].

Stanford, BL ;

Zondor, SD .

ANNALS OF PHARMACOTHERAPY, 2003, 37 (12) :1825-1830

[23] Bortezomib for the treatment of multiple myeloma [J].

Grosicki, Sebastian ;

Barchnicka, Agnieszka ;

Jurczyszyn, Artur ;

Grosicka, Anida .

EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (02) :173-185

[24] Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma [J].

Ghosh, Nilanjan ;

Ye, Xiaobu ;

Ferguson, Anna ;

Huff, Carol Ann ;

Borrello, Ivan .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (05) :593-599

[25] Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma [J].

Cho, Yukiko ;

Hori, Mitsuo ;

Okoshi, Yasushi ;

Fujisawa, Fumie ;

Shinagawa, Atsushi ;

Kudo, Daisuke ;

Komeno, Takuya ;

Yoshida, Chikashi ;

Katsura, Yukitaka ;

Ota, Ikuyo ;

Shimizu, Seiichi ;

Kamoshita, Masaharu ;

Sasaki, Katsuhiro ;

Tanaka, Keiji ;

Mukai, Harumi Y. ;

Kojima, Hiroshi .

ACTA HAEMATOLOGICA, 2015, 134 (01) :25-31

[26] Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma [J].

Lamm, W. ;

Drach-Schauer, B. ;

Eder, S. ;

Drach, J. .

ONCOLOGY, 2013, 85 (04) :223-227

[27] Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy [J].

J R Berenson ;

J D Hilger ;

O Yellin ;

R Dichmann ;

D Patel-Donnelly ;

R V Boccia ;

A Bessudo ;

L Stampleman ;

D Gravenor ;

S Eshaghian ;

Y Nassir ;

R A Swift ;

R A Vescio .

Leukemia, 2014, 28 :1529-1536

[28] Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy [J].

Berenson, J. R. ;

Hilger, J. D. ;

Yellin, O. ;

Dichmann, R. ;

Patel-Donnelly, D. ;

Boccia, R. V. ;

Bessudo, A. ;

Stampleman, L. ;

Gravenor, D. ;

Eshaghian, S. ;

Nassir, Y. ;

Swift, R. A. ;

Vescio, R. A. .

LEUKEMIA, 2014, 28 (07) :1529-1536

[29] Bortezomib-induced neurogenic bladder in patients with multiple myeloma [J].

Shimura, Kazuho ;

Shimazaki, Chihiro ;

Taniguchi, Kyoko ;

Inaba, Tohru ;

Horiike, Shigeo ;

Taniwaki, Masafumi .

ANNALS OF HEMATOLOGY, 2009, 88 (04) :383-384

[30] Bortezomib-induced painful neuropathy in patients with multiple myeloma [J].

Bilinska, Malgorzata ;

Usnarska-Zubkiewicz, Lidia ;

Pokryszko-Dragan, Anna .

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2013, 17 (05) :421-426

← 1 2 3 4 5 →